Printer Friendly

NATIONAL RESEARCH COUNCIL CANADA APPROVALS CDN. $348,000 TO SPECTRAL DIAGNOSTICS

 TORONTO, July 28 /PRNewswire/ -- Spectral Diagnostics Inc. (NASDAQ: DIAGF; CDN: SPTR), the developer of a systems approach to cardiac diagnostics, reported today that the National Research Council Canada, an agency of the government of Canada, has approved a new financial contribution of approximately Cdn. $348,000 to the company for research and development of a rapid format diagnostic membrane based on liquid flow dynamics and referred to as Printed Liquidic Circuits. The Printed Liquidic Circuit was originally conceived at the Wolfson Applied Technology Laboratory, The University of Birmingham, Great Britain. During the funding period of 18 months, Spectral Diagnostics Inc., in collaboration with the Wolfson Applied Technology Laboratory, will develop and evaluate the Printed Liquidic Circuit for use in the next generations of Spectral's Cardiac Panel Tests.
 In making the announcement, Douglas C. Ball, chairman and CEO of Spectral Diagnostics Inc., said, "This new financial contribution, the third we have received from the National Research Council Canada, is especially pleasing to us as it not only provides support in the development of Spectral's next generation of cardiac diagnostics but, in our view, also represents NRCC's continued confidence in Spectral's pioneering research and development activities in the field of cardiac diagnostics."
 "The Printed Liquidic Circuit," the Spectral chairman explained, "is simple to use and easy to manufacture. The Printed Liquidic Circuit, in combination with existing dry chemistry technology, will strategically position the company against more than one segment of the cardiac diagnostic market. Our manufacturer, Princeton BioMedica Inc., a leader in mass production of rapid format diagnostics, uses Spectral's antibodies on its proprietary dry chemistry rapid format membrane which is well suited to hospital emergency departments and clinical laboratories."
 The company also announced that Spectral scientist, Garth Styba, has been invited to present an abstract at the BIAsymposium to be held on Aug. 1-4 at the California Institute of Technology (Caltech), Pasadena, Calif., entitled "The Characterization of Polyclonal Chicken IgY Antibodies Utilizing a New Reagent, `The MaCFc.'"
 Commenting on the Spectral abstract, Mr. Ball said, "The presentation of an abstract at the BIAsymposium to be held at Caltech, further reinforces our commitment to cardiac research and development. We are not just another diagnostic company layering product on the cardiac community. Rather, we are part of that community, with a corporate dedication to advancing knowledge in cardiac diagnostics."
 Spectral has developed a systems approach to cardiac diagnostics. Located at its Toronto laboratories, Spectral Diagnostics Inc.'s 30 scientists and support staff is entirely focused on cardiac diagnostic research and development that will result in new and novel products aimed at improving health care and containing health care costs. In Spectral's systems approach to cardiac diagnostics, patient care and care-giver needs are matched from the point of entry into the health care system through to discharge.
 Resulting from Spectral's cardiac diagnostic research and development, is a complete range of cardiac proteins and antibodies that are continually being enhanced according to characteristics of specificity and sensitivity along with greater clinical and prognostic utility in cardiac patient care. Spectral's cardiac antibodies are suited for a variety of delivery platforms ranging from rapid format panel tests used at the entry point of patients into the health care system, to automated diagnostic systems used to monitor cardiac patients progress through to discharge.
 The cardiac Panel Tests contain one or more of the cardiac markers Myoglobin, CK-MB, Myosin Light Chain and Troponin-I. The Cardiac Panel Tests, slightly larger than a credit card, are easy to use, require only a few drops of the patient's blood and provide a diagnosis in approximately 8 minutes.
 Clinical trials evaluating Spectral's Cardiac Panel Tests are in progress at two leading Canadian teaching hospitals. Spectral believes that the Cardiac Panel Test containing Myoglobin, Myosin Light Chain, CK-MB and Troponin-I will, for the first time, diagnose and distinguish, within several minutes, heart from non-heart ailments and unstable angina from heart attack.
 Beta-site clinical trials have also been arranged at five leading teaching hospitals located in the United States. At least another 30 hospitals located in numerous industrialized countries have expressed an interest in conducting beta-site clinical trials with the company.
 Spectral's common shares are listed on the NASDAQ Exchange in the United States and the Canadian Dealing Network (CDN) in Canada. Spectral's trading symbols are DIAGF (common shares) and DIAGWF (redeemable warrants) on the NASDAQ Exchange and SPTR (common shares) and SPTR.WT (redeemable warrants) on the Canadian Dealing Network (CDN).
 -0- 7/28/93
 /CONTACT: Douglas C. Ball, chairman and CEO of Spectral Diagnostics, 416-626-3233, or Irving L. Straus, chairman of Straus Corporate Communications, 212-768-2477, for Spectral Diagnostics/
 (DIAGF)


CO: Spectral Diagnostics Inc. ST: IN: MTC SU:

SH-PS -- NY008 -- 6613 07/28/93 08:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 28, 1993
Words:783
Previous Article:PILGRIM STATION RETURNS TO FULL POWER OPERATION AFTER BRIEF OUTAGE
Next Article:WARNER-LAMBERT ANNOUNCES GLOBAL PARTNERSHIP WITH WELLCOME P.L.C.
Topics:


Related Articles
SPECTRAL DIAGNOSTICS REPORTS CLINICAL TRIALS UNDERWAY FOR PROPRIETARY, IN-VITRO DIAGNOSTIC CARDIAC PANEL TEST; REPORTS FIRST QUARTER RESULTS
NATIONAL RESEARCH COUNCIL CANADA APPROVES ADDITIONAL CDN. $250,000 TO SPECTRAL DIAGNOSTICS INC.
SPECTRAL DIAGNOSTICS CALLS 736,200 REDEEMABLE COMMON STOCK PURCHASE WARRANTS TO PURCHASE SHARES FOR US$8 PER SHARE; REALIZES US$5,889,600
LEE D. FLOWERS, VICE PRESIDENT, BAXTER DIAGNOSTICS INC., A SUBSIDIARY OF BAXTER INTERNATIONAL, APPOINTED DIRECTOR OF SPECTRAL DIAGNOSTICS INC.
SPECTRAL DIAGNOSTICS APPOINTS EVP AND OPERATIONS OFFICER, POSITIONING COMPANY FOR COMMERCIALIZATION OF ITS CARDIAC DIAGNOSTIC PRODUCTS IN 1994
SPECTRAL DIAGNOSTICS INC. REPORTS RESULTS FOR THIRD FISCAL QUARTER AND NINE MONTHS ENDED DEC. 31, 1993
SPECTRAL DIAGNOSTICS INC. REPORTS RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 1994
SPECTRAL DIAGNOSTICS INC. REPORTS RESULTS FOR THE FISCAL YEAR ENDED MARCH 31, 1995
SPECTRAL DIAGNOSTICS INC. ANNOUNCES FINANCIAL RESULTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 1995
ATTENTION BUSINESS/FINANCIAL EDITORS:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters